Dutasteride/tamsulosin

Dutasteride/tamsulosin
Combination of
Dutasteride5α-Reductase inhibitor
TamsulosinAlpha-1 blocker
Clinical data
Trade namesJalyn
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: X (High risk)
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
KEGG

Dutasteride/tamsulosin, sold under the brand name Jalyn among others, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH). It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.[1]

Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010.[2] In June 2011, the FDA approved a label change warning of "Increased Risk of High-grade Prostate Cancer" from Jalyn.[3]

References

  1. 1 2 "Jalyn- dutasteride and tamsulosin hydrochloride capsule". DailyMed. Retrieved 28 December 2020.
  2. ↑ http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022460Orig1s000Approv.pdf
  3. ↑ https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm262877.htm
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.